Prostate cancer

GEC-ESTRO Handbook: https://user-swndwmf.cld.bz/20-Prostate-Cancer-GEC-ESTRO-Handbook-of-Brachytherapy

Nagore G, Moreno-Olmedo E, Suárez-Gironzini V, Aakki L, Li RG, Gómez E, Garcia A, Beltran L, Gomez-Iturriaga A. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer. Radiother Oncol. 2023 Sep;186:109807. doi: 10.1016/j.radonc.2023.109807. 

Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007. 

Salembier C, Rijnders A, Henry A, Niehoff P, André Siebert F, Hoskin P. Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection.  J Contemp Brachytherapy. 2013 Jun;5(2):63-9 

Salembier C, Henry A, Pieters BR, Hoskin P.  A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate (125)I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial.  J Contemp Brachytherapy. 2020 Feb;12(1):1-5. 

Groom N, Tsang Y, Lowe G, Hoskin P  Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer.  Brachytherapy. 2021 Mar-Apr;20(2):302-306 

Slevin F, Sethugavalar B, Al-Qaisieh B, Bownes P, Mason J, Smith J, Bottomley D, Henry AM. Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. J Contemp Brachytherapy. 2020 Dec;12(6):540-546. doi: 10.5114/jcb.2020.101686.

Joshua Mason, Ann Henry, Peter Bownes. Error detection thresholds for routine real time in vivo dosimetry in HDR prostate brachytherapy. Radiotherapy and Oncology 2020: 149:38-43 

Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Wilkinson C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM. A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clin Transl Radiat Oncol. 2019 Oct 14;20:1-8. doi:10.1016/j.ctro.2019.10.00 

Van der Meer MC, Bosman PAN, Niatsetski Y, Alderliesten T, van Wieringen N, Pieters BR, Bel A. Bi-objective optimization of catheter positions for high-dose-rate prostate brachytherapy. Med Phys. 2020 Dec;47(12):6077-6086. doi: 10.1002/mp.14505. 

Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, Milickovic N, Zamboglou N. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol. 2018 Feb;126(2):270-277. doi: 10.1016/j.radonc.2017.09.038. 

Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rödel C, Baltas D, Tselis N. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol. 2018 Aug;128(2):301-307. doi: 10.1016/j.radonc.2018.04.031.